This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Pharmaceuticalcompanies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. Gareth has been with the Clinical Research Network since 2009.
Tanja Dowe is the CEO of Debiopharm Innovation Fund, the strategic investment arm of the Swiss pharmaceuticalcompany Debiopharm. A former entrepreneur and strategy and transaction consultant, she steers the fund to invest in start-ups with disruptive technologies that transform the pharmaceutical industry. . About the author.
In this episode of our Health Innovators series, Paul Tunnah interviews Graeme Duncan, CEO of specialty pharmaceuticalcompany Advanz Pharma. Graeme discusses his career in the life sciences industry and how Advanz Pharma positions itself as the go-to partner for companies commercialising complex medicines in Europe.
Bringing an end to a 13-year deliberation on a whistleblower lawsuit, Biogen recently agreed to pay a $900 million settlement , amidst increased government alertness on pharmaceutical fraud. In 2009, Tysabri was performing well, having yielded $776 million in sales after being first approved in 2004, as per Biogen’s 2009 financial filings.
Since the start of the year, pharmaceuticalcompanies have been riding a rollercoaster of challenges. Dr Paul Tunnah founded pharmaphorum in 2009, which combines industry leading publications ( www.pharmaphorum.com ) with a specialist strategy and content marketing/communications consultancy ( www.pharmaphorumconnect.com ).
This heightened focus from regulators is shifting the type of deals pharmaceuticalcompanies are willing to execute, Baral noted. These mega deals created behemoth companies that needed to spread capital too thin and included redundancies due to unrealised synergies.
In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. So, how do smaller pharmaceuticalcompanies at the cutting edge get ready for their acquisition milestone, so they maximise their value and attractiveness?
According to Eurostat, only 57 percent of people in the 55-74 age group use the internet regularly, and only 54 percent of Europeans possess basic digital skills The Pharmaceutical Group of the European Union (PGEU) presents a compelling argument against the proposed POD policy. Article 63 EMA (29 January 2020).
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.
For pharmaceuticalcompanies there are a number of implications. For pharmaceuticalcompanies, this may mean a change in patient journeys to pharmacotherapy becoming longer and more complex, but also occurring in different settings. It will take a decade to fully evaluate the true impact.
Like most pharma companies of its size, Pfizer has faced its fair share of controversy as one of the most well-known drugmakers in the world. Since the turn of the millennium, Pfizer has embarked on a series of mega-mergers, gobbling up Warner-Lambert in 2000, Pharmacia and Upjohn in 2002, Wyeth in 2009, and Medivation in 2016.
Pharmaceutical advertising is a crucial aspect of promoting and marketing drugs to the public. With the increase in competition, it has become essential for pharmaceuticalcompanies to find the most effective methods of advertisement to reach their target audience. ” Pharmacy and Therapeutics, 2009.
He was referring to his business’ share of misconduct related fines that, between 2009 and 2017, topped $342 billion across the US and Europe. It’s killing us.” As the sector looks to maintain its momentum, it must be wary that positive messaging and increased scrutiny does not end up as a recipe for a hard fall.
IMPACT (now part of Syner-G BioPharma Group) has been providing Regulatory Affairs support to a mid-size pharmaceuticalcompany since 2009. Even though this company has a Regulatory Affairs Department, their rapid growth over the years has made “in-sourcing” of help a necessity.
It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals. As understanding of biological systems has forged ahead, pharmaceuticalcompanies have made increasing use of biotechnology in discovering and manufacturing new medicines.
In 2009, IMPACT (now part of Syner-G BioPharma Group) was contracted by a mid-size global pharmaceuticalcompany to prepare 2 Phase 3 clinical study reports (CSRs) for a biologic agent for the treatment of Crohn’s disease. Download a PDF of this case study. Establishment of a Long-Term Medical Writing Partnership.
Camilla has a well-recognised track record working with various multinational companies, including AstraZeneca, Novartis and Allergan. About the author.
Shots: Drug patent expiry is when a patent granted to a pharmaceuticalcompany for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years. No generic version of Entresto has been approved in the US.
RSV researchers at major pharmaceuticalcompanies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceuticalcompanies are pushing to develop drugs and vaccines for RSV with these populations in mind.
“The business integration from 2005 to 2007 of the two separate companies to form the joint Daiichi Sankyo created one of Japan’s biggest pharmaceuticalcompanies.” ” “The use of generic drugs is low in Japan, but health costs are increasing and the government has to do something to reduce costs.
Pharmaceuticalcompanies, regulatory agencies and governments are becoming increasingly concerned about fraud and counterfeiting throughout the pharmaceutical supply chain, especially with the cost of drugs going up.
Since the start of 2013, pharmaceuticalcompanies based in the U.S. The FDA apparently gave the company a green light to keep manufacturing and allowed ongoing generic drug export to the U.S. The Chinese company, Zhejiang HuaHai Pharmaceuticalcompany in Linhai, China, had changed its manufacturing process.
The company expects to commence P-I clinical trials on metastatic and pediatric primary bone cancer patients. Other radiotherapies under the company's pipeline include Humalutin and Alpha37. The company is evaluating Iomab-B in a P-III clinical trial (SIERRA) in patients with relapsed or refractory acute myeloid leukemia (AML).
After the outbreak of any epidemic or pandemic, all the responsibilities come on the shoulders of pharmaceuticalcompanies. With unprecedented diseases lurking on the corner, pharmaceuticalcompanies, are now obligated to widen their conventional horizons and look for substitute practices in their drug development strategies.
model is a holistic approach to incorporate the same strategy to life science and pharmaceuticalcompanies. A globally fast-growing, and largest pharmaceuticalcompany in the world was created through a merger between Pfizer and Pharmacia. Model: Inspired by the industry 4.0 model, the pharma 4.0
A pharmaceutical quality system (PQS) is a management system used to direct and control a pharmaceuticalcompany with regard to quality. link] 11 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline Q8 (R2): Pharmaceutical Development.”
To further expedite the introduction of the biosimilar globally, EirGenix has been in talks with global pharmaceuticalcompanies about licensing the marketing rights to EG1206A 5. The P-III trial of EG1206A is expected to be initiated shortly, estimated that the evaluation of the primary EPs will be completed within 2yrs.
www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations 5 US Food and Drug Administration. ICH Q10 Pharmaceutical Quality System.” April 2009. By nature of their business, pharmaceuticalcompanies are more risk-centric than other sectors, such as banking. March 2023.
Slaoui rose through the ranks at the big UK pharma and was appointed head of the company’s vaccines division in 2009, leaving in 2017 when Emma Walmsley took over as CEO at GSK.
So, this was back in 2009, and I hosted a Halloween party at my house, and I decided to dress up as Hunter S. You know, in November 2009, the FDA held a public hearing about the promotion of Food and Drug Administrative Related Regulated Medical Products, using the internet and social media tools. So, I didn’t look so bad.
9 As such, major investment is warranted for pharmaceuticalcompanies to fully capitalize on the benefits of CM, and they need to make the hard business choice of investing time and money—with added risk—to widen their manufacturing portfolio versus putting money in established technologies that have been profitable.
Large-molecule drugs such as biologics are particularly sensitive to foreign contamination and E&L interaction, making these issues key concerns for pharmaceuticalcompanies. In addition, packaging components are not entirely manufactured in a clean room environment, making them a potential source of exogenous contamination.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content